Bioavailability of low-dose vs high-dose 6-mercaptopurine

Carola A.S. Arndt, Frank M. Balis, Cynthia Lester McCully, Susan L. Jeffries, Karen Doherty, Robert Murphy, David G. Poplack

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The bioavailability of oral 6-mercaptopurine (6MP) at standard doses is very low, largely as a result of extensive first-pass metabolism by xanthine oxidase. Fewer than one third of patients achieve 6MP plasma concentrations known to be cytocidal in vitro (>1 μmol/L). Studies in vitro have suggested that first-pass metabolism can be saturated at higher doses of 6MP. To determine whether saturation occurs in vivo at clinically used doses and whether bioavailability can be enhanced by increasing the dose, the bioavailability of different doses of 6MP was studied first in rhesus monkeys and then in children with acute lymphoblastic leukemia in remission. In monkeys a higher dose of 6MP resulted in enhanced bioavailability, whereas in patients the mean relative bioavailability at the higher dose was significantly less. However, all patients achieved cytocidal (>1 to 10 μmol/L) plasma concentrations at the higher dose without manifesting significant clinical toxicity. Therefore cytocidal levels of 6MP can be achieved in patients with oral 6MP without the risk of unexpectedly high levels caused by saturation of first-pass metabolism.

Original languageEnglish (US)
Pages (from-to)588-591
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume43
Issue number5
StatePublished - May 1988
Externally publishedYes

Fingerprint

6-Mercaptopurine
Biological Availability
Xanthine Oxidase
Macaca mulatta
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Haplorhini

ASJC Scopus subject areas

  • Pharmacology

Cite this

Arndt, C. A. S., Balis, F. M., McCully, C. L., Jeffries, S. L., Doherty, K., Murphy, R., & Poplack, D. G. (1988). Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clinical Pharmacology and Therapeutics, 43(5), 588-591.

Bioavailability of low-dose vs high-dose 6-mercaptopurine. / Arndt, Carola A.S.; Balis, Frank M.; McCully, Cynthia Lester; Jeffries, Susan L.; Doherty, Karen; Murphy, Robert; Poplack, David G.

In: Clinical Pharmacology and Therapeutics, Vol. 43, No. 5, 05.1988, p. 588-591.

Research output: Contribution to journalArticle

Arndt, CAS, Balis, FM, McCully, CL, Jeffries, SL, Doherty, K, Murphy, R & Poplack, DG 1988, 'Bioavailability of low-dose vs high-dose 6-mercaptopurine', Clinical Pharmacology and Therapeutics, vol. 43, no. 5, pp. 588-591.
Arndt CAS, Balis FM, McCully CL, Jeffries SL, Doherty K, Murphy R et al. Bioavailability of low-dose vs high-dose 6-mercaptopurine. Clinical Pharmacology and Therapeutics. 1988 May;43(5):588-591.
Arndt, Carola A.S. ; Balis, Frank M. ; McCully, Cynthia Lester ; Jeffries, Susan L. ; Doherty, Karen ; Murphy, Robert ; Poplack, David G. / Bioavailability of low-dose vs high-dose 6-mercaptopurine. In: Clinical Pharmacology and Therapeutics. 1988 ; Vol. 43, No. 5. pp. 588-591.
@article{d7680c533d024189928edbb42c5166e6,
title = "Bioavailability of low-dose vs high-dose 6-mercaptopurine",
abstract = "The bioavailability of oral 6-mercaptopurine (6MP) at standard doses is very low, largely as a result of extensive first-pass metabolism by xanthine oxidase. Fewer than one third of patients achieve 6MP plasma concentrations known to be cytocidal in vitro (>1 μmol/L). Studies in vitro have suggested that first-pass metabolism can be saturated at higher doses of 6MP. To determine whether saturation occurs in vivo at clinically used doses and whether bioavailability can be enhanced by increasing the dose, the bioavailability of different doses of 6MP was studied first in rhesus monkeys and then in children with acute lymphoblastic leukemia in remission. In monkeys a higher dose of 6MP resulted in enhanced bioavailability, whereas in patients the mean relative bioavailability at the higher dose was significantly less. However, all patients achieved cytocidal (>1 to 10 μmol/L) plasma concentrations at the higher dose without manifesting significant clinical toxicity. Therefore cytocidal levels of 6MP can be achieved in patients with oral 6MP without the risk of unexpectedly high levels caused by saturation of first-pass metabolism.",
author = "Arndt, {Carola A.S.} and Balis, {Frank M.} and McCully, {Cynthia Lester} and Jeffries, {Susan L.} and Karen Doherty and Robert Murphy and Poplack, {David G.}",
year = "1988",
month = "5",
language = "English (US)",
volume = "43",
pages = "588--591",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Bioavailability of low-dose vs high-dose 6-mercaptopurine

AU - Arndt, Carola A.S.

AU - Balis, Frank M.

AU - McCully, Cynthia Lester

AU - Jeffries, Susan L.

AU - Doherty, Karen

AU - Murphy, Robert

AU - Poplack, David G.

PY - 1988/5

Y1 - 1988/5

N2 - The bioavailability of oral 6-mercaptopurine (6MP) at standard doses is very low, largely as a result of extensive first-pass metabolism by xanthine oxidase. Fewer than one third of patients achieve 6MP plasma concentrations known to be cytocidal in vitro (>1 μmol/L). Studies in vitro have suggested that first-pass metabolism can be saturated at higher doses of 6MP. To determine whether saturation occurs in vivo at clinically used doses and whether bioavailability can be enhanced by increasing the dose, the bioavailability of different doses of 6MP was studied first in rhesus monkeys and then in children with acute lymphoblastic leukemia in remission. In monkeys a higher dose of 6MP resulted in enhanced bioavailability, whereas in patients the mean relative bioavailability at the higher dose was significantly less. However, all patients achieved cytocidal (>1 to 10 μmol/L) plasma concentrations at the higher dose without manifesting significant clinical toxicity. Therefore cytocidal levels of 6MP can be achieved in patients with oral 6MP without the risk of unexpectedly high levels caused by saturation of first-pass metabolism.

AB - The bioavailability of oral 6-mercaptopurine (6MP) at standard doses is very low, largely as a result of extensive first-pass metabolism by xanthine oxidase. Fewer than one third of patients achieve 6MP plasma concentrations known to be cytocidal in vitro (>1 μmol/L). Studies in vitro have suggested that first-pass metabolism can be saturated at higher doses of 6MP. To determine whether saturation occurs in vivo at clinically used doses and whether bioavailability can be enhanced by increasing the dose, the bioavailability of different doses of 6MP was studied first in rhesus monkeys and then in children with acute lymphoblastic leukemia in remission. In monkeys a higher dose of 6MP resulted in enhanced bioavailability, whereas in patients the mean relative bioavailability at the higher dose was significantly less. However, all patients achieved cytocidal (>1 to 10 μmol/L) plasma concentrations at the higher dose without manifesting significant clinical toxicity. Therefore cytocidal levels of 6MP can be achieved in patients with oral 6MP without the risk of unexpectedly high levels caused by saturation of first-pass metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0023875321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023875321&partnerID=8YFLogxK

M3 - Article

C2 - 3365920

AN - SCOPUS:0023875321

VL - 43

SP - 588

EP - 591

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -